<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02788006</url>
  </required_header>
  <id_info>
    <org_study_id>FFCD 1404 - REGOLD</org_study_id>
    <nct_id>NCT02788006</nct_id>
  </id_info>
  <brief_title>Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .</brief_title>
  <acronym>REGOLD</acronym>
  <official_title>Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years Old With a Metastatic Colorectal Adenocarcinoma .</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter prospective phase II study evaluating regorafenib in older patients with
      metastatic colorectal cancer
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor control rate</measure>
    <time_frame>2 months</time_frame>
    <description>Number of patients with a complete or partial response or in stability 2 months after the beginning of treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Colorectal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Regorafenib 160 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib 160 mg</intervention_name>
    <arm_group_label>Regorafenib 160 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic colorectal cancer with histological proof

          -  Measurable disease according RECIST 1.1

          -  Age ≥ 70 years

          -  ECOG ≤ 1

          -  Biological values Haemoglobin ≥ 9 g/dL, PNN ≥ 1500/mm3, platelets≥ 100 000/mm3,
             bilirubin ≤ 1,5N, ASAT, ALAT et PAL ≤ 2,5N (≤ 5N if hepatic metastases), lipase ≤1,5N,
             TP≥ 70%, Creatinine clairance ≥ 30 mL/min

          -  Patient without response to 5FU chemotherapy or anti-vegf treatment or anti EGFR
             treatment (if RAS wild-type), in progression during this treatment or treatment
             stopped because of toxicities

          -  Geriatric Questionnaires answered

          -  Life-expectancy ≥ 3 months

          -  Informed Consent Signed

        Exclusion Criteria:

          -  Not able to swallow tablets (crushed tablets are not allowed)

          -  Previous treatment with regorafenib or other multikinase treatment

          -  Other cancer during the last 5 years, excepted in-situ cervix cancer, skin cancer non
             melanoma and cancer of the bladder curatively treated

          -  Radiotherapy: with extended fields in the last 4 weeks, with limited fields in the
             last 2 weeks previous inclusion

          -  Toxicity &gt; grade 1 not resolved with previous treatment

          -  Major surgery in the 28 days before the inclusion

          -  Non cicatrized injury, ulcer or bone fracture

          -  Congestive Cardiac insufficiency classe &gt;2 (NYHA)

          -  Unstable angor in the last 3 months

          -  Myocardial Infraction in the 6 months before inclusion

          -  HTA not controlled

          -  Pheochromocytome

          -  Arterial or venous thromboembolism in the past 6 months

          -  Infection of grade &gt; 2

          -  VIH infection

          -  B or C hepatitis necessiting a specific treatment

          -  Cirrhosis

          -  Suspicion of brain metastasis or brain metastasis

          -  Haemorraghe ofgrade &gt;3 in the last weeks

          -  Symptomatic Pulmonary fibrosis

          -  Proteinuria &gt; grade 3

          -  Malabsorption

          -  Allergy know to the treatment or to one similar treatment or to one treatment
             component

          -  Systemic anti-cancer drug during the study or the the last 4 weeks

          -  Concomitant treatment with CYP3A4 inhibitor or inductor or with UGT1A9 inhibitor

          -  Social, psychological or medical condition which can interfere with the study
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas APARICIO, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Avicenne BOBIGNY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Bacless</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oncologie et Radiothérapie</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Cap d'Or</name>
      <address>
        <city>La Seyne Sur Mer</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caluire et Cuire - Infirmerie Protestante de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Lyon Sud (HCL) - Pierre Benite</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital privé Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU - Hôpital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR - Service HGE</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Annecy Genevois</name>
      <address>
        <city>Pringy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital privé</name>
      <address>
        <city>Villeneuve D'Ascq</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>May 20, 2016</study_first_submitted>
  <study_first_submitted_qc>May 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2016</study_first_posted>
  <last_update_submitted>February 13, 2019</last_update_submitted>
  <last_update_submitted_qc>February 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

